A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma.

Abstract:

:Fourteen patients with refractory or metastatic adenocarcinoma of the endometrium were treated with continuous infusion vinblastine. No patient had a response. One patient had stable disease. Although well tolerated, vinblastine sulfate given by this method has no activity in this malignancy.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Kavanagh JJ,Saul PB,Wharton JT,Rutledge FN

doi

10.1016/0090-8258(87)90279-4

subject

Has Abstract

pub_date

1987-02-01 00:00:00

pages

236-9

issue

2

eissn

0090-8258

issn

1095-6859

pii

0090-8258(87)90279-4

journal_volume

26

pub_type

杂志文章
  • Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.

    abstract:OBJECTIVE:Conization aims to remove pre-neoplastic lesions of the uterine cervix. Several techniques for conization have been compared, but evidence regarding the most effective therapeutic option is scant. Here, we aimed to compare the recurrence rate following laser conization and loop electrosurgical excision proced...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.025

    authors: Bogani G,DI Donato V,Sopracordevole F,Ciavattini A,Ghelardi A,Lopez S,Simoncini T,Plotti F,Casarin J,Serati M,Pinelli C,Valenti G,Bergamini A,Gardella B,Dell'acqua A,Monti E,Vercellini P,Fischetti M,D'Ippolito G,Agu

    更新日期:2020-12-01 00:00:00

  • Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

    abstract::Fifty-one patients with advanced ovarian cancer FIGO III were studied to determine new tumor biology-oriented prognostic factors. The tumor-associated protease urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 were detected in malignant ovarian cancer tissue extracts. The concentration of both factors...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1313

    authors: Kuhn W,Pache L,Schmalfeldt B,Dettmar P,Schmitt M,Jänicke F,Graeff H

    更新日期:1994-12-01 00:00:00

  • Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.

    abstract::Epithelial ovarian carcinoma consists of not one, but several, entities. A number of subtypes exist, including high-grade and low-grade serous carcinomas, clear cell, endometrioid carcinoma and mucinous carcinoma. Historically, women with epithelial ovarian cancer have been treated similarly and "lumped" in the same c...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2014.11.078

    authors: Groen RS,Gershenson DM,Fader AN

    更新日期:2015-02-01 00:00:00

  • Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens.

    abstract:OBJECTIVE:The origins and clinical significance of endosalpingiosis (ES), ectopic tubal epithelium, are not well understood. These investigations aim to characterize ES as it relates to normal fallopian tube, ovarian surface and serous neoplasms. METHODS:A retrospective review of pathology reports from all prophylacti...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.12.007

    authors: Esselen KM,Ng SK,Hua Y,White M,Jimenez CA,Welch WR,Drapkin R,Berkowitz RS,Ng SW

    更新日期:2014-02-01 00:00:00

  • Insomnia and its association with quality of life in women with ovarian cancer.

    abstract:OBJECTIVES:Insomnia is common in women with ovarian cancer but there are limited prospective data on the frequency and degree of impact on patients. Our objective was to determine the prevalence of insomnia over the first three years after a diagnosis of ovarian cancer; and the relationship between insomnia and quality...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.06.500

    authors: Ross TL,DeFazio A,Friedlander M,Grant P,Nagle CM,Williams M,Webb PM,Beesley VL,OPAL Study Group.

    更新日期:2020-09-01 00:00:00

  • Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?

    abstract:OBJECTIVE:To analyze corpus cancer patients with a breast cancer history for risk of developing aggressive uterine histologic types. METHODS:Corpus cancer patients with a history of breast cancer were identified from the Surveillance Epidemiology and End Results database from 1988 to 2001. Demographics, clinico-pathol...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.01.014

    authors: Chan JK,Manuel MR,Cheung MK,Osann K,Husain A,Teng NN,Rao A,Carlson RW,Whittemore AS

    更新日期:2006-09-01 00:00:00

  • Endometrial carcinoma: transvaginal ultrasonography prediction of depth of myometrial invasion.

    abstract::Myometrial invasion greater than 33% negatively affects the prognosis of endometrial carcinoma. Since the endometrium is readily differentiated from myometrium via high-resolution transvaginal sonography (TVS), this prospective study was undertaken to evaluate the efficacy of TVS in determining the depth of myometrial...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90023-x

    authors: Sahakian V,Syrop C,Turner D

    更新日期:1991-12-01 00:00:00

  • Lymph node sampling in patients with epithelial ovarian carcinoma.

    abstract::Lymph node sampling is part of the FIGO staging of patients with ovarian carcinoma and is usually part of a meticulous second look operation. We analyzed the primary lymph node status of patients and compared this to the lymph node status at second look operation. From 3/86-3/91, 97 patients with epithelial ovarian tu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90097-3

    authors: Goldberg GL,Scheiner J,Friedman A,O'Hanlan KA,Davidson SA,Runowicz CD

    更新日期:1992-11-01 00:00:00

  • Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.

    abstract:OBJECTIVE:To determine whether chemotherapy-induced neutropenia (C-iN) is associated with improved survival in a population of primary advanced ovarian cancer and peritoneal carcinoma patients treated with a carboplatin plus paclitaxel chemotherapy backbone. METHODS:A post-hoc exploratory analysis of Gynecologic Oncol...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.03.013

    authors: Tewari KS,Java JJ,Gatcliffe TA,Bookman MA,Monk BJ

    更新日期:2014-06-01 00:00:00

  • Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

    abstract:OBJECTIVE:Wee1-like kinase (Wee1) is a tyrosine kinase which negatively regulates entry into mitosis at the G2 to M-phase transition and has a role in inhibition of unscheduled DNA replication in S-phase. The present study investigated the clinical role of Wee1 in advanced-stage (FIGO III-IV) ovarian serous carcinoma. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.07.102

    authors: Slipicevic A,Holth A,Hellesylt E,Tropé CG,Davidson B,Flørenes VA

    更新日期:2014-10-01 00:00:00

  • Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.

    abstract:BACKGROUND:The aim of this study was to assess prognostic factors and implications on further management in a large series of stage-II or III Atypical Proliferative Serous Tumors (APST) with a long-term follow-up. PATIENTS AND METHODS:Patients with APSTs and peritoneal implants treated in, or referred to, our institut...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.06.489

    authors: Maria S,Faron M,Maulard A,Pautier P,Leary A,Chargari C,Genestie C,Gouy S,Morice P

    更新日期:2020-09-01 00:00:00

  • Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.

    abstract:PURPOSE:A phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of capecitabine in women with measurable platinum-sensitive ovarian cancer or platinum-sensitive primary peritoneal cancer and to explore the ability of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and th...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.ygyno.2004.11.037

    authors: Garcia AA,Blessing JA,Lenz HJ,Darcy KM,Mannel RS,Miller DS,Husseinzadeh N,Gynecologic Oncology Group.

    更新日期:2005-03-01 00:00:00

  • Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.

    abstract:OBJECTIVES:In this study, we examine the sensitivity of a panel of ovarian carcinoma cells, which includes four primary ovarian cancer cell samples, and four normal ovarian epithelium samples to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We also examine the intracellular regulation of TRAIL-mediat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.03.029

    authors: Lane D,Cartier A,L'Espérance S,Côté M,Rancourt C,Piché A

    更新日期:2004-06-01 00:00:00

  • Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.

    abstract:OBJECTIVES:Endometriosis-associated ovarian carcinoma (EAOC) has recently received increasing attention due to its suggested biological behavior, distinctive from those of usual epithelial ovarian cancer. To elucidate some of the controversies on this intriguing entity, a series of patients with EAOC were compared to o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2001.6382

    authors: Erzen M,Rakar S,Klancnik B,Syrjänen K

    更新日期:2001-10-01 00:00:00

  • Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.

    abstract:OBJECTIVE:Preoperative identification of cervical stromal invasion in endometrial carcinoma is important to select patients for primary radical hysterectomy. The objective of this prospective implementation study was to assess if introduction of magnetic resonance imaging (MRI) in addition to the standardly applied end...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.05.009

    authors: Haldorsen IS,Berg A,Werner HM,Magnussen IJ,Helland H,Salvesen OO,Trovik J,Salvesen HB

    更新日期:2012-09-01 00:00:00

  • Association between high risk papillomavirus DNA and nitric oxide release in the human uterine cervix.

    abstract:OBJECTIVE:Local cervical factors may determine the outcome of human papillomavirus (HPV) infection. Nitric oxide (NO) may be one such factor, since it is produced by uterine cervical cells and it takes part in both immunological and carcinogenic reactions. We studied the association between the presence of cervical hig...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.05.003

    authors: Rahkola P,Mikkola TS,Ylikorkala O,Vaisanen-Tommiska M

    更新日期:2009-08-01 00:00:00

  • Neuroendocrine (Merkel cell) carcinoma of the vulva: a case report and review of the literature.

    abstract::The clinical and pathologic features of a vulvar neuroendocrine (Merkel cell) neoplasm are presented. Cytologic studies of material obtained from needle aspiration suggested that the tumor was a small cell neoplasm possibly of neuroendocrine derivation. The light-microscopic findings of sheets of small, uniform cells ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90053-8

    authors: Copeland LJ,Cleary K,Sneige N,Edwards CL

    更新日期:1985-11-01 00:00:00

  • Is attendance at an ovarian cancer screening clinic a worry-reducing event? Findings from pre- to post-screening.

    abstract:OBJECTIVE:Many studies have examined the relationship between worry and cancer screening. Due to methodological inconsistencies, results of these studies have varied and few conclusions can be made when generalizing across studies. The purpose of the current study was to better understand the worry-cancer screening rel...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2016.11.047

    authors: Ruberg JL,Helm CW,Felleman BI,Helm JE,Studts JL

    更新日期:2017-02-01 00:00:00

  • Role of hysterectomy in management of gestational trophoblastic disease.

    abstract:OBJECTIVE:To evaluate incidence, indications, and outcome of hysterectomy in women presenting with gestational trophoblastic disease. METHODS:A prospective observational study using a standardized protocol for registration, assessment, and treatment of gestational trophoblastic disease. A total of 5976 consecutive new...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.2002.6814

    authors: Pisal N,North C,Tidy J,Hancock B

    更新日期:2002-11-01 00:00:00

  • Screening as a prognostic factor in cervical cancer: analysis of survival and prognostic factors based on Icelandic population data, 1964-1988.

    abstract::Survival rates were computed for 376 women diagnosed with carcinoma of the uterine cervix between 1964 and 1988. The 5-year survival rate for the entire group was 63%. The effect of age at diagnosis, clinical stage, histopathology, year of diagnosis, and screening program attendance was studied by univariate analysis ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90011-s

    authors: Sigurdsson K,Hrafnkelsson J,Geirsson G,Gudmundsson J,Salvarsdóttir A

    更新日期:1991-10-01 00:00:00

  • Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.

    abstract:OBJECTIVE:To determine the impact of geographic location on advanced-stage ovarian cancer care adherence to the National Comprehensive Cancer Network (NCCN) guidelines in relation to race and socioeconomic status (SES). METHODS:Patients diagnosed with stage IIIC/IV epithelial ovarian cancer (1/1/96-12/31/06) were iden...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.03.561

    authors: Bristow RE,Chang J,Ziogas A,Anton-Culver H,Vieira VM

    更新日期:2014-07-01 00:00:00

  • Fatal radiation hepatitis: a case report and review of the literature.

    abstract::A case of fatal radiation hepatitis occurring after treatment with 2200 rad given by the moving strip technique is presented. This fatality occurred in a 28-year-old woman with persistent ovarian carcinoma despite prolonged chemotherapy. Scans of the liver using computerized tomography, 99mTc sulfur colloid, and 99mTc...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90316-1

    authors: Schacter L,Crum E,Spitzer T,Maksem J,Diwan V,Kolli S

    更新日期:1986-07-01 00:00:00

  • Retroperitoneal leiomyosarcoma: eight cases and a literature review.

    abstract::Leiomyosarcoma, a rare malignancy of smooth muscle, may arise from the retroperitoneum and present with the same vague symptoms as a malignancy of the pelvic organs. The purpose of this paper is to review eight cases of retroperitoneal leiomyosarcoma and to illustrate the presenting symptoms, prognostic indicators, an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1995.9967

    authors: Todd CS,Michael H,Sutton G

    更新日期:1995-12-01 00:00:00

  • Sarcoma in association with multimodality management of vulvar cancer: two case reports.

    abstract:BACKGROUND:Radiation-induced or -associated sarcoma is a rare event which has been well described in the literature. However, this entity has been infrequently described in association with genital tract malignancies. To our knowledge it has never been described in association with the management of vulvar cancer. CAS...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2001.6139

    authors: Hyde S,Uitterhoeve LJ,Schilthuis MS,ten Kate FJ,van der Velden J

    更新日期:2001-05-01 00:00:00

  • Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.

    abstract:OBJECTIVE:A multicenter phase II trial was conducted to assess the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with high-dose-rate intracavitary brachytherapy (HDR-ICBT) using a low cumulative prescribed dose schedule in patients with locally advanced uterine cervical cancer. METHODS:The Japanese Gyne...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2012.04.036

    authors: Toita T,Kitagawa R,Hamano T,Umayahara K,Hirashima Y,Aoki Y,Oguchi M,Mikami M,Takizawa K,Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG).

    更新日期:2012-08-01 00:00:00

  • Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.

    abstract:OBJECTIVE:This study aimed to evaluate the prognostic value of quantitative metabolic parameters measured on F-18 FDG PET/CT (FDG PET/CT) at the time of the first relapse in patients with relapsed epithelial ovarian cancer (EOC). METHODS:Fifty-six relapsed EOC patients were retrospectively included. Quantitative metab...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.12.032

    authors: Kim CY,Jeong SY,Chong GO,Son SH,Jung JH,Kim DH,Lee SW,Ahn BC,Lee J

    更新日期:2015-03-01 00:00:00

  • Uterine leiomyosarcoma: A review of the literature and update on management options.

    abstract::Uterine leiomyosarcoma is the most common type of uterine sarcoma. It is an extremely aggressive malignancy associated with a poor overall prognosis. Women affected may vary in age, but are most often diagnosed in their perimenopausal years. Presenting symptoms may be vague and mimic other benign uterine conditions. P...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2018.09.010

    authors: Roberts ME,Aynardi JT,Chu CS

    更新日期:2018-12-01 00:00:00

  • The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data.

    abstract:OBJECTIVE:This article critically reviews the literature on the association between endometriosis and gynecological cancers and breast cancer, based on epidemiologic data. METHODS:Literature review of the English language literature based on searching in the MEDLINE (PubMed) database and additional collection of repor...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2011.06.017

    authors: Munksgaard PS,Blaakaer J

    更新日期:2011-10-01 00:00:00

  • Epigenetics of ovarian cancer: from the lab to the clinic.

    abstract:OBJECTIVE:Ovarian cancer remains the most lethal gynaecological cancer. Various molecular changes have been identified and have shown promise for their diagnostic, prognostic and curative capacity but still need further validation. Among different mechanisms, the present article reviews the importance of epigenetic cha...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2010.03.015

    authors: Asadollahi R,Hyde CA,Zhong XY

    更新日期:2010-07-01 00:00:00

  • A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

    abstract:BACKGROUND:A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer. METHODS:Women with histologically confirmed persistent/recurrent endometrial cancer were treated with 500mg oral gefitinib daily until progression or severe toxicity, wit...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2013.02.019

    authors: Leslie KK,Sill MW,Fischer E,Darcy KM,Mannel RS,Tewari KS,Hanjani P,Wilken JA,Baron AT,Godwin AK,Schilder RJ,Singh M,Maihle NJ

    更新日期:2013-06-01 00:00:00